Elicio Therapeutics, Inc. financial data

Symbol
ELTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
451 D Street, 5 Th Floor, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Angion Biomedica Corp. (to 5/30/2023)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 164 % -69.8%
Debt-to-equity 253 %
Return On Equity -555 % -1439%
Return On Assets -157 % -118%
Operating Margin -2.61K % -2183%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares +28.4%
Common Stock, Shares, Outstanding 10.3M shares +22.6%
Entity Public Float 47.1M USD +37.3%
Common Stock, Value, Issued 103K USD +22.6%
Weighted Average Number of Shares Outstanding, Basic 11.3M shares +290%
Weighted Average Number of Shares Outstanding, Diluted 11.3M shares +290%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 653K USD -97.8%
Research and Development Expense 29.2M USD +147%
General and Administrative Expense 12.2M USD +137%
Costs and Expenses 41.3M USD +144%
Operating Income (Loss) -41.3M USD -122%
Nonoperating Income (Expense) 2.67M USD +1595%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -38.7M USD -31.3%
Earnings Per Share, Basic 18.6 USD/shares +75.5%
Earnings Per Share, Diluted 18.6 USD/shares +75.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.43M USD -84.2%
Other Assets, Current 405K USD -12%
Assets, Current 6.69M USD -74.5%
Property, Plant and Equipment, Net 597K USD -35%
Operating Lease, Right-of-Use Asset 6.14M USD -11.7%
Other Assets, Noncurrent 864K USD +1008%
Assets 15.8M USD -58.1%
Accounts Payable, Current 1.06M USD -75.3%
Employee-related Liabilities, Current 1.11M USD -25.5%
Accrued Liabilities, Current 5.32M USD +130%
Contract with Customer, Liability, Current 350K USD
Liabilities, Current 7.59M USD -0.16%
Operating Lease, Liability, Noncurrent 5.57M USD -13.3%
Other Liabilities, Noncurrent 81K USD
Liabilities 17.4M USD +23.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -238K USD -11800%
Retained Earnings (Accumulated Deficit) -161M USD -31.5%
Stockholders' Equity Attributable to Parent -1.65M USD -107%
Liabilities and Equity 15.8M USD -58.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -48.9%
Net Cash Provided by (Used in) Financing Activities 11M USD +9.8%
Net Cash Provided by (Used in) Investing Activities 3K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 10.3M shares +22.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -158%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.51M USD -79.8%
Deferred Tax Assets, Valuation Allowance 90.1M USD +223%
Deferred Tax Assets, Gross 47.2M USD +15.6%
Operating Lease, Liability 6.42M USD -13.3%
Depreciation 82K USD -25.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.9M USD -75.5%
Lessee, Operating Lease, Liability, to be Paid 8.05M USD -15.8%
Property, Plant and Equipment, Gross 1.99M USD -7.05%
Operating Lease, Liability, Current 854K USD -13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD +2.52%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.35M USD -5.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.63M USD -24.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 60.7M USD +217%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.1M USD -4.81%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +2.95%
Operating Lease, Payments 379K USD +21.5%
Additional Paid in Capital 160M USD +9.35%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.35M USD +43.9%
Interest Expense 753K USD -89.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%